160 related articles for article (PubMed ID: 32060402)
1. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.
Oberley MJ; Raikar SS; Wertheim GB; Malvar J; Sposto R; Rabin KR; Punia JN; Seif AE; Cahen VC; Schore RJ; Luca DC; Guinipero T; Woods WG; O'Gorman MRG; Orgel E
Leukemia; 2020 Jul; 34(7):1741-1750. PubMed ID: 32060402
[TBL] [Abstract][Full Text] [Related]
2. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
4. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
[TBL] [Abstract][Full Text] [Related]
7. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
9. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
10. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.
Orgel E; Alexander TB; Wood BL; Kahwash SB; Devidas M; Dai Y; Alonzo TA; Mullighan CG; Inaba H; Hunger SP; Raetz EA; Gamis AS; Rabin KR; Carroll AJ; Heerema NA; Berman JN; Woods WG; Loh ML; Zweidler-McKay PA; Horan JT;
Cancer; 2020 Feb; 126(3):593-601. PubMed ID: 31661160
[TBL] [Abstract][Full Text] [Related]
11. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
Huang A; Huang C; Tang G; Cheng H; Liu M; Ding J; Gong S; Chen Q; Zhang W; Yang J; Wang J; Hu X
Leuk Lymphoma; 2018 May; 59(5):1073-1083. PubMed ID: 28857648
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
[TBL] [Abstract][Full Text] [Related]
13. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Berry DA; Zhou S; Higley H; Mukundan L; Fu S; Reaman GH; Wood BL; Kelloff GJ; Jessup JM; Radich JP
JAMA Oncol; 2017 Jul; 3(7):e170580. PubMed ID: 28494052
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
16. Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.
Myint HH; Tandon S; Narula G; Prasad M; Subramanian P; Patkar N; Tembhare P; Gujral S; Banavali S
J Pediatr Hematol Oncol; 2020 Oct; 42(7):415-419. PubMed ID: 32976349
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
18. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
19. Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E; Merker M; Salzmann-Manrique E; Kreyenberg H; Krenn T; Dürken M; Faber J; Huenecke S; Cappel C; Bremm M; Willasch A; Bakhtiar S; Jarisch A; Soerensen J; Klingebiel T; Bader P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):87-95. PubMed ID: 27742575
[TBL] [Abstract][Full Text] [Related]
20. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]